
iOnctura has announced the expansion of its clinical trial programme for its lead pipeline asset, roginolisib.
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

